KRAS Mutations in Pancreatic Cancer

KRAS is the single most commonly altered gene in pancreatic cancer. A change (mutation) in the KRAS gene is found in roughly 90 percent of pancreatic ductal adenocarcinomas, the most common type of pancreatic cancer, meaning that for most patients, a KRAS mutation is part of what drives the tumor. A “biomarker” is a measurable feature of cancer, such as a change in a gene, that provides doctors with information they cannot get from looking at cells under the microscope alone. KRAS testing has become important in pancreatic cancer because, after many years in which this gene could not be targeted by any drug, the first treatments directly targeting mutated KRAS are now reaching patients and entering clinical trials.

This article will help you understand what a KRAS result means on a pathology report for pancreatic cancer, why the test is done, how it is performed, and how the result may guide treatment decisions. A KRAS mutation in pancreatic cancer is not inherited and is not passed down to children. It is a change that happened within the tumor itself. Its importance is twofold: it is so common that it helps confirm the nature of the cancer, and the specific KRAS mutation type is increasingly used to match patients to targeted drugs and clinical trials.

What is KRAS?

KRAS is a gene that gives cells the instructions to make a protein, also called KRAS, that acts like an on/off switch for cell growth. The KRAS protein sits just inside the cell membrane and relays “grow and divide” signals from the cell surface to its control center. Normally this switch flips on only when the cell receives the right signal, and then flips off again, so growth happens in a controlled way.

A mutation in the KRAS gene can jam this switch in the “on” position. When that happens, the cell receives a constant grow-and-divide signal even when it should stop, and this continuous signaling is one of the main forces driving pancreatic cancer. Almost all KRAS mutations in pancreatic cancer occur at a single site in the gene, codon 12. The change at this spot is written with a letter-number-letter code that names the exact substitution, such as G12D, G12V, or G12R. Knowing which one is present matters, because the newest targeted drugs are designed to fit one specific version of the mutated protein.

Why is KRAS testing done in pancreatic cancer?

KRAS testing in pancreatic cancer is done for two main reasons, both tied to the fact that a KRAS mutation is present in about 90 percent of these cancers and is a central driver of tumor growth. First, the result helps complete the molecular picture of the cancer, which is increasingly part of the standard workup for pancreatic ductal adenocarcinoma. Second, and increasingly important, the specific KRAS mutation identifies which targeted drugs and clinical trials a patient may be eligible for.

The specific version of the KRAS mutation matters because targeted drugs are designed for particular versions. In pancreatic cancer, the most common are G12D (around 40 percent of cases), G12V (around 30 percent), and G12R (around 15 percent), while the G12C version that is more common in lung cancer occurs in only about 1 to 2 percent of pancreatic cancers. Because treatment options vary depending on the specific mutation present, testing reports the exact change rather than simply stating that KRAS is mutated. KRAS testing is most relevant when the cancer is advanced or has spread, since that is the setting in which these targeted therapies and trials are considered.

A smaller but important group of pancreatic cancers, roughly 8 to 10 percent, have no KRAS mutation. These are called KRAS wild-type, meaning the gene is in its normal, unmutated form. KRAS wild-type pancreatic cancers are more likely to carry other targetable changes, such as gene fusions involving NRG1, ALK, NTRK, RET, or BRAF. For this reason, a result showing no KRAS mutation is itself grounds to look carefully for other alterations, usually through broad molecular profiling.

How is KRAS testing performed in pancreatic cancer?

KRAS testing in pancreatic cancer looks for a mutation in the KRAS gene and, importantly, identifies exactly which mutation is present. The test is performed on a tumor sample, so it usually does not require an additional procedure. In pancreatic cancer, the sample often comes from a small biopsy taken with a fine needle during an endoscopic ultrasound, or from tissue removed at surgery. Two types of laboratory method are commonly used.

Next-generation sequencing (NGS) — Next-generation sequencing reads many genes at once and is the preferred approach in pancreatic cancer. It detects the specific KRAS mutation and, at the same time, checks for other relevant alterations, including BRCA and PALB2 changes, mismatch repair genes, and fusions more common in KRAS wild-type tumors. This single broad test gives the fullest picture from a limited biopsy sample.
Polymerase chain reaction (PCR) — PCR-based tests are designed to directly detect common KRAS mutations. They are fast and sensitive, but they check only for the specific mutations they are designed to find, so they may not capture rarer changes or other genes that broad sequencing covers.

In some situations, KRAS can also be tested using a blood sample, called a liquid biopsy, which looks for tumor DNA circulating in the bloodstream. This can be useful when a tissue sample is difficult to obtain or when doctors want to monitor the cancer over time.

How are KRAS results reported in pancreatic cancer?

KRAS results in pancreatic cancer describe whether a mutation was found in the KRAS gene and, when one is found, which specific mutation is present. Results usually appear in the molecular testing or biomarker section of the pathology report, described in one of the following ways.

KRAS mutation detected (positive) — A mutation was found in the KRAS gene. The report will name the specific mutation, such as G12D, G12V, or G12R. This exact change is what determines which targeted drugs and trials may apply.
No KRAS mutation detected (wild-type or negative) — No mutation was found in the KRAS gene. The report may use the term “wild-type,” meaning the normal form of the gene. In pancreatic cancer this less common result is a prompt to look carefully for other targetable changes, such as NRG1, ALK, NTRK, RET, or BRAF fusions.
Specific mutation named (for example, KRAS G12C) — When the report names a particular version, it is matching the result to the targeted drugs designed for that version. The G12C version is uncommon in pancreatic cancer but is specifically named because approved drugs exist for it in other cancers and are being studied here.

What does a KRAS result mean for pancreatic cancer treatment?

The KRAS result in pancreatic cancer tells the treatment team which targeted options and clinical trials may be appropriate, based on whether a KRAS mutation is present and which specific variant it is. The pathology report does not prescribe treatment; the KRAS result is one of several findings the medical oncology team weighs together when discussing options with the patient. For most of the history of pancreatic cancer, KRAS could not be targeted by any drug, and treatment relied on chemotherapy. That picture is now changing.

For the small group of patients whose cancer carries the KRAS G12C version, the drugs sotorasib and adagrasib, which are already approved for G12C-mutated lung cancer, can be considered, often through a clinical trial in pancreatic cancer. For the much larger group with G12D and other common versions, a newer generation of drugs designed to block those specific mutated proteins is being studied in clinical trials, with encouraging early results. A separate group of medicines called pan-RAS inhibitors, which block mutated KRAS regardless of the exact version, is also in trials; one such drug, daraxonrasib, has been reported to improve survival compared with chemotherapy in a large trial of previously treated pancreatic cancer. These therapies are still being studied rather than established as standard care, so for many patients the most direct way to access KRAS-targeted treatment today is through a clinical trial. The oncology team can explain which trials and options apply to a specific KRAS result.

When no KRAS mutation is present, attention turns to other targetable changes that are more common in KRAS wild-type pancreatic cancer, including NRG1, ALK, NTRK, RET, and BRAF fusions, several of which have corresponding targeted therapies. Regardless of KRAS status, the treatment plan also takes into account other biomarkers tested at the same time, including BRCA and PALB2 mutations (which can indicate eligibility for PARP inhibitors) and mismatch repair status (which can indicate eligibility for immunotherapy). These are described in separate articles.

Does a KRAS mutation in pancreatic cancer have prognostic meaning?

In pancreatic cancer, the presence of a KRAS mutation, the change that drives most of these tumors, also carries some information about outlook. As a group, KRAS-mutant pancreatic cancers tend to have a less favorable course than the smaller group of KRAS-wild-type cancers. Among the different KRAS variants, evidence on whether any specific mutation predicts a better or worse outcome than another is still developing and is not yet used to inform routine treatment decisions. The main value of identifying the specific mutation today is to match the cancer to targeted drugs and trials, rather than to predict outcome. KRAS status is always interpreted alongside the stage of the cancer, whether it can be removed with surgery, and the other findings on the report.

Is a KRAS mutation inherited?

The KRAS mutation found in pancreatic cancer is not inherited and is not passed down to children. It is a “somatic” mutation, meaning it developed within the pancreatic cancer cells during a person’s lifetime rather than being present in the genes a person is born with. Because the mutation is present only in the tumor and not in the body’s other cells, it does not appear on a test for inherited cancer risk and has no implications for family members. This differs from some other findings reported in pancreatic cancer, such as inherited BRCA1 or BRCA2 mutations, which can be passed through families and are evaluated separately. A KRAS result is purely about understanding and guiding treatment for the cancer that is already present.

What happens after KRAS testing?

Once KRAS testing on the pancreatic cancer is complete, the result becomes part of the information the treatment team uses to plan care. The specific KRAS result, whether a common mutation such as G12D, the less common G12C, or no mutation at all, is considered alongside the stage of the cancer, whether it can be removed by surgery, the other biomarker results, and the patient’s overall health. For an advanced cancer with a KRAS mutation, the team considers whether a KRAS-targeted drug or a clinical trial is an option. When no KRAS mutation is present, the focus shifts to the other targetable changes that are more common in that setting.

Pancreatic cancer care usually involves a multidisciplinary team that may include a medical oncologist, a surgeon, a radiation oncologist, a gastroenterologist, a pathologist, and, when inherited risk is being evaluated, a genetic counselor. The medical oncologist typically leads decisions about systemic therapy, including chemotherapy and any targeted or trial options. Because KRAS-targeted therapy for pancreatic cancer is a fast-moving area, asking whether new options or trials have become available is reasonable at any point in care. Regular imaging and follow-up visits are used to track how the cancer is responding to treatment.

Questions to ask your doctor

Was my pancreatic cancer tested for a KRAS mutation, and what was the result?
If a mutation was found, which specific version is it, such as G12D, G12V, G12R, or G12C?
Does my specific KRAS result make me eligible for any targeted drug or clinical trial?
Was my testing done by next-generation sequencing, and did it also check for other targetable changes?
If no KRAS mutation was found, was my cancer checked for fusions such as NRG1, ALK, NTRK, RET, or BRAF?
How does my KRAS result fit together with my other biomarker results, such as BRCA, PALB2, or mismatch repair status?
Are there clinical trials of KRAS-targeted therapy that I should consider?
Does my KRAS result tell us anything about my prognosis?
Does my KRAS result have any implications for my family members?
If new KRAS-targeted treatments become available during my care, how will we know?